Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05779163
PHASE1/PHASE2

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

Sponsor: Nanjing Leads Biolabs Co.,Ltd

View on ClinicalTrials.gov

Summary

This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.

Official title: A Multicenter, Open Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-033 in the Treatment of Patients With Advanced Malignant Tumors.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

468

Start Date

2023-04-14

Completion Date

2026-03-31

Last Updated

2025-05-07

Healthy Volunteers

No

Interventions

DRUG

LBL-033 for Injection

Initial dose - MTD; Q2W; intravenous infusion

Locations (6)

Fujian Cancer Hospital

Fuzhou, Fujian, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Liaoning Cancer Hospital & Institute

Shenyang, Liaoning, China

Obstetrics & Gynecology Hospital of Fudan University

Shanghai, Shanghai Municipality, China

West China Second University Hospital,Sichuan University

Chengdu, Sichuan, China